HUTCHMED China Ltd (0013)
Hong Kong Stock Exchange · Hong Kong · prices in HKD · close of 23 Oct 2026
Key indicators
| Last close | HKD 22.56 |
|---|---|
| 52-week range | 15.57 – 25.58 |
| Return, 1 month / 3 months | +0.1% / +27.2% |
| Return, 1 year / 3 years | −3.7% / −16.6% |
| Trend | Uptrend |
| RSI (14) | 55 |
| Volatility (1 year) | 35.6% |
| Worst drawdown (1 year) | -37.8% |
| Average daily value traded | 115.00M HKD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
HUTCHMED China is a biopharmaceutical company that discovers, develops and commercialises medicines, chiefly targeted cancer therapies and immunotherapies, for patients in China and other markets. It also runs a consumer health business that makes and sells over-the-counter medicines and health supplements. The company is based in Hong Kong and carries out research, manufacturing and sales through operations in mainland China and elsewhere, serving hospitals, physicians and patients alongside retail consumers of its health products.
The shares are listed on the Hong Kong Stock Exchange in Hong Kong under the code 0013, and the price on this page is in Hong Kong dollars (HKD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
HUTCHMED China Ltd (0013) trades on the Hong Kong Stock Exchange in Hong Kong. It last closed at HKD 22.56 on 23 October 2026.
Its price-based Market X-Ray is 80 out of 100 (a strong price profile), ranking 94 of 2,613 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 3.7% and over the last three months it rose 27.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Hong Kong Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 83 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 8.2% | ||
| From 52-week high | -11.3% | ||
| Momentum | 76 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 27.2% | ||
| 6-month return | 2.9% | ||
| 12-month return, skipping the last month | -3.8% | ||
| Stability (higher is calmer) | 74 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 35.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -37.8% | ||
| Liquidity | 92 · Strong | Trades actively. | |
| Average daily value traded | 115.00M HKD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +1.3% |
|---|---|
| 1 month | +0.1% |
| 3 months | +27.2% |
| 6 months | +2.9% |
| 1 year | −3.7% |
| 3 years | −16.6% |
| 5 years | −55.2% |
Signals
| 50-day / 200-day average | 21.28 / 20.85 |
|---|---|
| Golden / death cross (60 days) | Golden, 7 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.00 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Hong Kong Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.